Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Sanchez-Sanchez, Juan Luis; Giudici, Kelly V.; Guyonnet, Sophie; Delrieu, Julien; Li, Yan; Bateman, Randall J.; Parini, Angelo; Vellas, Bruno; de Souto Barreto, Philipe

doi:10.1186/s13195-021-00940-2

Alzheimer's Research & Therapy

Table 5 Evolution in memory outcomes according to combined plasma MCP-1 and Aβ42/40 status

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Period	Aβ42/40^−a/MCP1^−b n = 195	Aβ42/40⁻/MCP1⁺ n = 85	Aβ42/40⁺ /MCP1⁻ n = 97	Aβ42/40⁺ /MCP1⁺ n = 52
Period	Between-group difference (95% CI)^c	Between-group difference (95% CI)^c	Between-group difference (95% CI)^c	Between-group difference (95% CI)^c
FCSRT free recall,n= 383
12 months	−1.10 (−1.47, −0.72)	−0.61 (−1.75, 0.52)	−3.26 (−4.87, −1.65) *	−2.74 (−4.76, −0.73)**
24 months	−0.46 (−0.86, −0.06)	−0.95 (−2.14, 0.25)	−4.24 (−5.94, −2.54) ***	−2.36 (−4.51, −0.21)*
36 months	−1.30 (−1.76, −0.84)	−1.58 (−2.90, −0.27)*	−4.46 (−7.64, −2.55) ***	−1.81 (−4.17, 0.54)
48 months	−1.47 (−1.97, −0.98)	−1.51 (−2.90, −0.11)*	−4.22 (−7.71, −2.17) ***	−3.31 (−5.89, −0.73)*
FCSRT total recall,n= 383
12 months	−0.60 (−0.84, −0.36)	−0.95 (−1.61, −0.30)	−2.24 (−3.17, −1.30)***	−1.88 (−3.06, −0.71)***
24 months	−0.18 (−0.45, 0.08)	−0.71 (−1.43, 0.004)	−2.29 (−3.31, −1.26)***	−1.92 (−3.22, −0.62)**
36 months	−0.92 (−1.24, −0.61)	−0.63 (−1.45, 0.18)	−2.32 (−3.53, −1.12)***	−2.08 (−3.56, −0.60)**
48 months	−0.81 (−1.17, −0.46)	−0.45 (−1.35, 0.45)	−3.14 (−4.48, −1.81)***	−2.54 (−4.22, −0.86)**
FCSRT free delayed recall,n= 383
12 months	−0.10 (−0.27, 0.06)	−0.25 (−0.70, 0.21)	−1.12 (−1.76, −0.48)***	−1.48 (−2.29, −0.68)**
24 months	−0.11 (−0.28, 0.07)	−0.28 (−0.76, 0.20)	−1.38 (−2.06, −0.70)***	−1.14 (−2.01, −0.28)*
36 months	−0.24 (−0.44, −0.04)	−0.61 (−1.14, −0.07)*	−1.37 (−2.15, −0.59)***	−0.86 (−1.82, 0.08)
48 months	−0.38 (−0.60, −0.17)	−0.69 (−1.26, −0.13)*	−1.90 (−2.74, −1.06)***	−1.28 (−2.33, −0.23)*
FCSRT total delayed recall,n= 383
12 months	−0.07 (−0.15, 0.01)	−0.22 ( −0.43, −0.01)*	−0.57 (−0.87, −0.26)***	−0.66 (−1.04, −0.28)***
24 months	−0.06 (−0.15, 0.03)	−0.32 (−0.57, −0.08)**	−0.72 (−1.07, −0.37)***	−0.51 (−0.95, −0.07)*
36 months	−0.25 (−0.36, −0.14)	−0.20 (−0.49, −0.08)	−1.00 (−1.43, −0.58)***	−0.46 (−0.98, 0.07)
48 months	−0.26 (−0.39 , −0.13)	−0.45 (−0.78, −0.13)**	−1.20 (−1.69, −0.72)***	−0.93 (−1.54, −0.31)**

*p value < 0.05; **p value < 0.001; ***p value < 0.001: significant differences in the evolution of the outcomes (Aβ42/40^-/MCP1⁻ as reference group)
^#p value < 0.05; ^##p value < 0.001;^###p value < 0.001: significant difference in the evolution of the outcomes between Aβ42/40⁺ /MCP1⁻ and Aβ42/40⁺ /MCP1⁺ groups
Models were adjusted by sex, age, BMI, MAPT group, CDR status at baseline, GDS score, and ApoE ε4 genotype
Abbreviations: Aβ42/40 β-amyloid 42aa isoform/β-amyloid 40aa isoform ratio, FCSRT Free and Cued Selective Reminding Test, MCP-1 Monocyte Chemoattractant Protein-1
^aAbnormal Aβ42/40 defined as values ≥ 107 pg/mL
^bAbnormal MCP-1 defined as values in the 4th quartile (> 251 pg/mL)
^cNegative values indicate worsening performance along follow-up

Back to article page

ISSN: 1758-9193

Contact us

Submission enquiries: kathrina.mendez@springernature.com
General enquiries: info@biomedcentral.com